Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adial Pharmaceuticals (ADIL) Liabilities and Shareholders Equity (2022 - 2024)

Adial Pharmaceuticals' Liabilities and Shareholders Equity history spans 3 years, with the latest figure at $6.7 million for Q3 2024.

  • For Q3 2024, Liabilities and Shareholders Equity rose 134.1% year-over-year to $6.7 million; the TTM value through Dec 2024 reached $18.3 million, up 20.03%, while the annual FY2023 figure was $4.7 million, 17.38% down from the prior year.
  • Liabilities and Shareholders Equity for Q3 2024 was $6.7 million at Adial Pharmaceuticals, up from $4.9 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $14.0 million in Q1 2022 and bottomed at $2.9 million in Q3 2023.
  • The 3-year median for Liabilities and Shareholders Equity is $5.7 million (2022), against an average of $6.5 million.
  • The largest annual shift saw Liabilities and Shareholders Equity crashed 72.06% in 2023 before it skyrocketed 134.1% in 2024.
  • A 3-year view of Liabilities and Shareholders Equity shows it stood at $5.7 million in 2022, then decreased by 17.38% to $4.7 million in 2023, then skyrocketed by 41.72% to $6.7 million in 2024.
  • Per Business Quant, the three most recent readings for ADIL's Liabilities and Shareholders Equity are $6.7 million (Q3 2024), $4.9 million (Q2 2024), and $6.7 million (Q1 2024).